Ascendis Health Limited (JSE:ASC)
South Africa · Delayed Price · Currency is ZAR · Price in ZAc | Market Cap | 575.69M +27.8% |
| Revenue (ttm) | n/a |
| Net Income | 11.28M -80.3% |
| EPS | 0.02 -80.3% |
| Shares Out | 625.75M |
| PE Ratio | 51.07 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 120,719 |
| Average Volume | 2,086,506 |
| Open | 96.00 |
| Previous Close | 92.00 |
| Day's Range | 92.00 - 96.00 |
| 52-Week Range | 71.00 - 113.00 |
| Beta | 0.20 |
| RSI | 43.88 |
| Earnings Date | Dec 24, 2025 |
About Ascendis Health
Ascendis Health Limited, a health and wellness company, provides health and wellness products and clinical and diagnostic medical devices in South Africa. It operates in Consumer Health and Medical Devices segments. The company offers multivitamins and minerals, micronutrients, and nutraceutical supplements; vitamins and homeopathic and herbal products; and over-the-counter, complementary, alternative consumer, skin, and scripted compounding products under the Solal, Solal Skincare, Chela-Preg, Bettaway, Chela-fer, Jungle-Vites, Vitaforce, and ... [Read more]
Financial Performance
Financial StatementsNews
Ascendis Wins FDA Approval For Rare Disease Therapy
Ascendis Pharma A/S (NASDAQ: ASND) shares are up during Monday’s premarket session following the FDA’s approval of Yuviwel (navepegritide; developed as TransCon CNP), the first and only once-weekly t...
Ascendis (ASND) Q4 2025 Earnings Call Transcript
Ascendis (ASND) Q4 2025 Earnings Call Transcript
Ascendis Confirms Durable Growth Benefits In Achondroplasia In COACH Trial
(RTTNews) - Ascendis Pharma A/S (ASND) announced positive topline data from the Week 52 COACH Phase 2 trial evaluating once-weekly TransCon CNP in combination with TransCon hGH in pediatric patients w...
Ascendis (ASND) Q3 2025 Earnings Call Transcript
Ascendis (ASND) Q3 2025 Earnings Call Transcript
Ascendis to Share Latest Endocrinology Rare Disease Data in 3 Oral Presentations at ASBMR 2025 ...
Ascendis to Share Latest Endocrinology Rare Disease Data in 3 Oral Presentations at ASBMR 2025 | ASND Stock News
Ascendis (ASND) Q2 2025 Earnings Call Transcript
Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term
Ascendis Pharma A/S (NASDAQ: ASND) released topline data on Monday from a trial that included 84 children with achondroplasia, a genetic disorder that causes dwarfism and disproportionate short statu...